en Adults Hematology & Oncology Adults Hematology & Oncology مقاله مروری Review Article <div style="text-align: justify;"><span style="font-size:14px;"><span style="line-height:2;"><span style="font-family:Times New Roman;"><strong>Background: </strong>Pancreatic cancer is one of the most aggressive and lethal malignancies, with limited treatment options and a poor prognosis. Recent research has highlighted the potential role of metformin, a widely used antidiabetic drug, in modulating cancer risk and progression. This review aims to explore the current evidence on the impact of metformin on pancreatic cancer outcomes and its potential mechanisms of action.<br> <strong>Materials and Methods: </strong>A comprehensive literature search was conducted using databases such as PubMed, Scopus, and Web of Science to identify studies investigating the relationship between metformin use and pancreatic cancer. Inclusion criteria encompassed clinical trials, cohort studies, and laboratory research published in the last two decades. Data extraction focused on patient outcomes, metformin dosage, study design, and proposed mechanisms of action.<br> <strong>Results: </strong>The review indicates that metformin use is associated with improved overall survival and reduced cancer incidence in patients with pancreatic cancer, particularly among those with concurrent diabetes. Mechanistic studies suggest that metformin exerts its anticancer effects through the inhibition of the mTOR pathway, reduction of insulin-like growth factors, and induction of autophagy. However, the results are heterogeneous, and several studies highlight the need for further clinical trials to establish causality and optimal therapeutic regimens.<br> <strong>Conclusion: </strong>While current evidence supports a potentially beneficial role of metformin in pancreatic cancer management, the findings are preliminary and require further validation through randomized controlled trials. The heterogeneity of the studies underscores the necessity for standardized protocols to assess the efficacy and safety of metformin as an adjunct therapy in pancreatic cancer treatment.</span></span></span></div> Metformin, Pancreatic Cancer, Molecular Pathways, Cancer Treatment, Cellular Energy, Metabolism 56 68 http://ijbc.ir/browse.php?a_code=A-10-1228-1&slc_lang=en&sid=1 Sepehr Ramezani sepehr.ramezany74@gmail.com 100319475328460011540 100319475328460011540 Yes Babol University of Medical Science, Babol, Iran. Dariush Moslemi moslemi_d@yahoo.com 100319475328460011541 100319475328460011541 No Babol University of Medical Science, Babol, Iran. Faezeh Firuzpour faezeh.1997@gmail.com 100319475328460011542 100319475328460011542 No Babol University of Medical Science, Babol, Iran. Hamidreza Didar hamidreza.didar@yahoo.com 100319475328460011543 100319475328460011543 No Shahid Beheshti University of Medical Science, Tehran, Iran. Seyedamirmohammad Mazloumi Amir.mazloumi1996@gmail.com 100319475328460011544 100319475328460011544 No Babol University of Medical Science, Babol, Iran. Narjes rezaeiroushan narjes.rezaee@gmail.com 100319475328460011545 100319475328460011545 No Azad University Sari Branch Faculty of Medicine, Sari, Iran.